Crossmark

A longitudinal study on symptom distress and management of transhepatic arterial interventional chemotherapy combined with targeted therapy and immunotherapy based on patient self-reported outcomes

Crossref DOI link: https://doi.org/10.1007/s44178-025-00156-6

Published Online: 2025-04-28

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bu, Liuxiu

Chen, MeiXian

Liu, ShuYue

Li, TianTian

Huang, ZhongYing https://orcid.org/0000-0002-9933-980X
Funding

Funding for this research was provided by:

Special Fund Project for Science and Technology Innovation Strategy of Guangdong Province (A2022031)
License Information

Text and Data Mining valid from 2025-04-28

Version of Record valid from 2025-04-28
More Information

Article History

Received: 20 October 2024

Revised: 21 March 2025

Accepted: 25 March 2025

First Online: 28 April 2025

Declarations

:

: The study received approval from the Ethics Committee of the Sun Yat-sen University Cancer Center(G2021-082–01), and informed consent was obtained from all participants.

: The authors agreed to publish this manuscript.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below